International scientists, researchers, physicians and patient advocates in the field of lung cancer and thoracic malignancies will tune in January 28-31, 2021, for the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC). Memorial Sloan Kettering (MSK) Medical Oncologist Bob T. Li, MD, PhD, MPH, will be featured as part of the WCLC Presidential Symposium. In his session on Saturday, January 30, he will present the registrational phase II data from the CodeBreaK 100 clinical study, evaluating investigational sotorasib (AMG 510) in 126 patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC).
The cancer gene KRAS (pronounced “kay-rass”) has been studied for almost 40 years and is responsible for many of the most common cancers, including about one-quarter of lung cancers and between one-third and one-half of colorectal cancers. However until recently, the KRAS protein was considered an “undruggable” target. In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated NSCLC and who harbor KRAS p.G12C mutations, validating CodeBreak 100’s phase I results, according to the research that will be presented at WCLC by Dr. Li. This research resulted in a Breakthrough Therapy Designation for sotorasib from the U.S. Food and Drug Administration (FDA), and regulatory filings have been submitted to the FDA and European Medicines Agency (EMA). More information about this research can be found here.
“This is a historic milestone in lung cancer therapy,” said Dr. Li. “Further clinical trials of sotorasib, either alone or in combination with other cancer drugs, are underway in an effort to potentially benefit even more patients.”
Several other MSK experts will present research during the Conference, including Thoracic Surgeon Prasad S. Adusumilli, MD, FACS, who will give an update on his research about translating CAR T cell therapy to solid tumors, and Medical Oncologist Paul K. Paik, MD, who will present about a phase II VISION study where tepotinib demonstrated durable efficacy and a tolerable safety in patients with NSCLC harboring METex14 skipping.